Agilon Health's Turnaround Plan Gets Its First Real Test Tomorrow

Agilon Health reports first-quarter 2026 earnings after the close on May 6, with analysts expecting the company to swing to a profit of $1.05 per share — a dramatic reversal from the $0.00 reported in Q1 2025. The central question is whether the value-based care platform can sustain its recent momentum after a volatile 2025 that saw the stock plunge on repeated earnings misses, only to rally sharply in early 2026 as sentiment improved. With the stock up 47% over the past 50 days and trading well above most moving averages, investors will be watching closely to see if management can deliver on the turnaround narrative or if another disappointment will derail the recovery.

Part 1: Earnings Preview

Agilon Health partners with independent primary care physicians to deliver value-based care for Medicare beneficiaries, assuming financial responsibility for patient populations through risk-sharing arrangements. The company provides the administrative, clinical, and operational infrastructure needed to support comprehensive care delivery, including data analytics, care management, and population health programs.

Agilon reports Q1 2026 earnings after the close on May 6, with the consensus estimate calling for $1.05 per share on revenue of approximately $1.41 billion. That would mark a sharp improvement from the $0.00 per share reported in Q1 2025 and represents a dramatic turnaround from the $-11.50 loss posted in the most recent quarter (Q4 2025). Year-over-year, the expected profit compares favorably to the breakeven result from the same quarter last year, signaling that analysts believe the company has turned a corner.

Three key themes define this earnings story:

1. Profitability Inflection: After four consecutive quarters of losses — including a disastrous Q4 2025 miss of $-11.50 versus $-6.75 expected — analysts are forecasting a return to profitability in Q1 2026. The question is whether Agilon can sustain positive earnings or if this is a one-quarter anomaly driven by seasonal factors or one-time items.

2. Revenue Trajectory and Member Growth: Revenue is expected to decline 10.2% year-over-year to $1.41 billion, a further deceleration from the 4.5% decrease in Q1 2025. Investors will be watching for commentary on member additions (the company added 8,000 customers in Q4 2025 to reach 511,000 total) and whether the revenue decline is stabilizing or accelerating.

3. Full-Year Guidance and Credibility: After missing revenue expectations in Q4 2025 and delivering full-year revenue guidance that "significantly" missed analyst expectations, management's credibility is on the line. Any update to full-year 2026 guidance — currently calling for a loss of $-6.35 per share — will be scrutinized for signs of conservatism or further deterioration.

Ahead of the release, analyst sentiment has deteriorated over the past month, with the average recommendation slipping from 3.05 to 2.95 (closer to Hold than Buy). However, the Barchart Technical Opinion has surged to 48% Buy from 80% Sell a month ago, reflecting the stock's sharp rally. Weiss Ratings maintains a "sell (e+)" rating, while Benchmark has a Buy rating with a $13 price target. Deutsche Bank holds at $33, and Wells Fargo raised its target to $37.50 following the Q4 report. The wide range of price targets — from $6.25 to $50.02 — underscores the uncertainty surrounding Agilon's turnaround prospects.

Part 2: Historical Earnings Performance

Agilon Health has a troubling track record of missing earnings estimates, with three of the past four quarters delivering negative surprises. The most recent quarter (Q4 2025) was particularly brutal: the company reported a loss of $-11.50 per share versus the $-6.75 consensus, a 70.37% miss that sent the stock tumbling. Q3 2025 saw a 50% miss ($-6.75 versus $-4.50 expected), and Q2 2025 delivered a 127.27% miss ($-6.25 versus $-2.75 expected). The only bright spot was Q1 2025, when Agilon reported breakeven results versus a $-0.25 expected loss, a 100% beat that briefly lifted sentiment.

The pattern is clear: Agilon has struggled to meet even lowered expectations, with losses deepening throughout 2025 despite analyst estimates that anticipated improvement. The magnitude of the misses has been severe — Q4's $-11.50 loss was nearly double the consensus — suggesting either operational challenges that management failed to communicate or a business model under more pressure than analysts anticipated. The Q1 2025 beat now looks like an outlier rather than the start of a trend, and investors will be watching closely to see if the $1.05 profit forecast for Q1 2026 is achievable or if another miss is in store.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Agilon Health reports after market close, meaning Day 0 reflects anticipation and after-hours trading, while Day +1 captures the first full session of market reaction.

Agilon Health's post-earnings price action has been extremely volatile, with an average absolute Day 0 move of 7.79% and an average Day +1 move of 18.50% — well above typical market reactions. The most dramatic move came after the August 2025 report, when the stock plunged 51.51% on Day +1 following a disappointing quarter. The February 2026 report (most recent) saw a 26.90% Day 0 surge and an 18.92% Day +1 gain, reflecting relief that the company had finally stabilized after a brutal 2025.

The Day +1 range averages 18.69%, indicating that the stock often continues to move significantly in the session following the initial reaction. Investors should expect double-digit percentage swings in either direction, with the potential for follow-through volatility extending beyond the immediate post-earnings session. The historical pattern suggests that misses are punished severely (see the August and November 2025 reactions), while any sign of stabilization or improvement can trigger sharp rallies.

Part 2.2: Options Market Expected Move

The options market is pricing in a 0.00% expected move for the May 15 expiration, which appears to be a data anomaly given the stock's historical earnings volatility. Based on the 18.50% average Day +1 move from past earnings reports, investors should expect a significantly larger reaction than the options data suggests. The disconnect likely reflects thin options liquidity (total open interest of just 1,519 contracts) rather than a genuine expectation of muted volatility.

Part 3: What Analysts Are Saying

Analysts remain cautious on Agilon Health, with a consensus rating of 2.95 (Hold) and an average price target of $22.54 — implying 15.7% downside from the current price of $26.74. The breakdown shows 2 Strong Buys, 14 Holds, 1 Moderate Sell, and 2 Strong Sells, reflecting a lack of conviction in either direction. The wide range of price targets — from a low of $6.25 to a high of $50.02 — underscores the uncertainty surrounding the company's turnaround prospects.

Sentiment has deteriorated over the past month, with the average recommendation slipping from 3.05 to 2.95 and one analyst downgrading from Hold to Strong Sell. The shift reflects lingering concerns about the company's ability to deliver on its profitability targets after a disastrous 2025. However, the fact that the consensus target sits below the current price suggests that the recent rally may have gotten ahead of fundamentals, and analysts are waiting for proof of execution before raising estimates.

The consensus price target of $22.54 implies that the stock is currently overvalued by 15.7%, a cautionary signal heading into earnings. If Agilon delivers another miss or issues disappointing guidance, the downside could be swift given the stock's recent run-up. Conversely, a strong beat and improved outlook could force analysts to raise targets and close the gap between the current price and the Street's view.

Part 4: Technical Picture

The Barchart Technical Opinion has surged to 48% Buy from 80% Sell a month ago and 24% Buy a week ago, reflecting the stock's sharp rally off the lows. The rapid improvement in the signal suggests that momentum has shifted decisively in favor of the bulls, though the "Weak" strength rating indicates that the trend is not yet firmly established.

Timeframe Analysis:

• Short-term (100% Buy): Strong buy signal indicates near-term momentum is overwhelmingly positive, with the stock in a clear uptrend heading into earnings.
• Medium-term (25% Sell): Moderate sell signal suggests that the intermediate-term trend remains cautious, reflecting the stock's volatile history and the need for sustained follow-through.
• Long-term (50% Buy): Neutral-to-bullish reading indicates that the longer-term trend is improving but not yet convincing, with the stock still working to repair damage from the 2025 selloff.

Trend Characteristics: The trend is characterized as Weak and Weakening, suggesting that while momentum is positive in the short term, the overall setup lacks conviction and could reverse quickly on disappointing news.

Agilon is trading above the 20-day ($25.77), 50-day ($18.16), 100-day ($18.16), and 200-day ($22.35) moving averages, but below the 5-day ($27.82) and 10-day ($27.32) averages — indicating that the stock has pulled back slightly after a strong run. The fact that the stock is well above the longer-term moving averages suggests that the rally has been substantial, but the recent dip below the 5- and 10-day averages could signal short-term exhaustion. The overall technical setup is supportive but fragile heading into earnings: the stock has momentum on its side, but the "Weakening" trend direction and the pullback from recent highs suggest that another earnings miss could trigger a sharp reversal. Conversely, a strong beat could propel the stock back above the short-term moving averages and extend the rally.